Physician profile
Jonathan Ryan Isgrig
NPI 1376953042
$3,095.10
in general payments reported to CMS, 2019-2025
22 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $303 · 2021: $453 · 2022: $212 · 2023: $812 · 2024: $480 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.72 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,046.82 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $592.61 | 2019-2021 | |
| Alcon Vision LLC | $271.61 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Coherus Oncology, INC. | $148.82 | 2023 | |
| Sun Pharmaceutical Industries INC. | $147.01 | 2021 | |
| Genentech USA, INC. | $125.36 | 2024 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $112.55 | 2019-2021 | |
| Allergan, INC. | $105.44 | 2019-2022 | |
| Ivantis, INC | $99.14 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $98.95 | 2021 | |
| Dompe US, INC. | $70.16 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $65.68 | 2019 | |
| New World Medical,INC. | $43.50 | 2019 | |
| Oyster Point Pharma, INC. | $43.05 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $20.53 | 2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $18.32 | 2024 | Idose |
| Apellis Pharmaceuticals, INC. | $17.39 | 2023 | Syfovre |
| Novartis Pharmaceuticals Corporation | $15.95 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.09 | 2023 | Eylea |
| Abbvie INC. | $13.99 | 2022 | |
| Rayner Intraocular Lenses Limited | $12.50 | 2022 | |
| Rxsight INC | $10.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Isgrig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.